Researchers target bat genes in quest for drug to combat Covid-19
- A team from China, Singapore and the US says an inhibitor molecule called carolacton could have pharmaceutical potential
- Gene-blocking compound might be able to stop replication of virus, scientists say
In a research paper published online on Monday, scientists from China, Singapore and the United States said carolacton, which inhibits a specific bat gene, could help suppress the infection of Sars-CoV-2, the coronavirus that causes Covid-19.
The joint paper was published on online archive bioRxiv by researchers from Tsinghua University, the Chinese Centre for Disease Control and Prevention, and the Chinese Academy of Sciences as well as teams from Singapore’s Duke – NUS Medical School and Duke University.
The paper has not been peer reviewed.
Pangolins may not have passed coronavirus on to humans, Chinese scientists say
The team examined the gene functions of the black fruit bat and found that carolacton inhibited MTHFD1, a key gene in the production of purine, a critical element in viral replication in both bats and people.
The team said MTHFD1 could be a potential target for developing broad-spectrum antiviral drugs.
“MTHFD1 knockdown blocks replication of multiple RNA viruses, including influenza virus, mumps virus, Melaka virus and Zika virus,” the paper said.
“Importantly, host cells have a higher tolerance for MTHFD1 inhibition than viruses, potentially providing a therapeutic window for targeting MTHFD1 with antiviral drugs.
“We tested the effect of carolacton on the infection of Sars-CoV-2 … [The result] supports a therapeutic window of this compound in potential clinical applications.”
The researchers said the development of an antiviral drug for Covid-19 would be similar to developing cancer drugs, because those drugs also targeted specific genes that cancer cells needed.
Sign up now and get a 10% discount (original price US$400) off the China AI Report 2020 by SCMP Research. Learn about the AI ambitions of Alibaba, Baidu & JD.com through our in-depth case studies, and explore new applications of AI across industries. The report also includes exclusive access to webinars to interact with C-level executives from leading China AI companies (via live Q&A sessions). Offer valid until 31 May 2020.